Listen Aphasia Pilot Study

Starting soon · Not applicable

Conditions studied: Aphasia, Malignant Brain Tumor

In brief

This is a feasibility and pilot study to refine and test LISTEN, an AI-based augmentative and alternative communication (AAC) smartphone app, integrated into the patient's personal electronic device, to augment and facilitate communication in patients with tumor-related aphasia (TRA) and their care partners. The study will assess the feasibility and acceptability of LISTEN in patients with TRA and their care partners.

Key facts

Study ID

NCT07732140

Run by

Dana-Farber Cancer Institute

People needed

80

Starts

2027-01-01

Expected to finish

2030-12-01

Last updated by the study team

2026-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient inclusion criteria are as follows:
• A histologically or cytologically confirmed primary or secondary brain tumor with expected ongoing deterioration in language as determined by their oncologist
• Mild-to-moderate aphasia or other acquired communication disorder as determined by their oncologist or speech-language pathologist
• ECOG Performance Status of ≤2 or Karnofsky Performance Status ≥60
• Expected overall survival of >6 months
• Ability to understand and the willingness to sign a written consent form
• Age ≥18 years
• Willingness to participate in study interviews and be recorded for the study (for monitoring of study fidelity)
• Cancer survivors will also be included
• Care-partner inclusion criteria are as follows:
• Identified by their patient as someone who is integral to their care
• Age ≥18 years
• Ability to understand and the willingness to sign a written consent form
• Willingness to participate in study interviews and be recorded for the study (monitoring of study fidelity)

You may not qualify if…

• Patient exclusion criteria are as follows:
• Unable to read or respond to questions in English
• Severe dysarthria as determined by their oncologist
• Aphasia that is moderate-to-sever enough that the patient cannot consent without a proxy
• Expected survival of ≤ 6 months
• Severe cognitive impairment as determined by their oncologist
• Care-partner exclusion criteria are as follows:
• Unable to read or respond to questions in English

Where it is running

• Brigham & Woman's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.